150 related articles for article (PubMed ID: 33573542)
41. Synthesis and biological evaluation of new 2-arylcarbonyl-3-trifluoromethylquinoxaline 1,4-di-N-oxide derivatives and their reduced analogues.
Solano B; Junnotula V; Marín A; Villar R; Burguete A; Vicente E; Pérez-Silanes S; Aldana I; Monge A; Dutta S; Sarkar U; Gates KS
J Med Chem; 2007 Nov; 50(22):5485-92. PubMed ID: 17910426
[TBL] [Abstract][Full Text] [Related]
42. Biological activity of esters of quinoxaline-7-carboxylate 1,4-di-N-oxide against E. histolytica and their analysis as potential thioredoxin reductase inhibitors.
Soto-Sánchez J; Caro-Gómez LA; Paz-González AD; Marchat LA; Rivera G; Moo-Puc R; Arias DG; Ramírez-Moreno E
Parasitol Res; 2020 Feb; 119(2):695-711. PubMed ID: 31907668
[TBL] [Abstract][Full Text] [Related]
43. Cyclic voltammetry of phenazines and quinoxalines including mono- and di-N-oxides. Relation to structure and antimicrobial activity.
Crawford PW; Scamehorn RG; Hollstein U; Ryan MD; Kovacic P
Chem Biol Interact; 1986 Oct; 60(1):67-84. PubMed ID: 3779885
[TBL] [Abstract][Full Text] [Related]
44. Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives.
Zarranz B; Jaso A; Aldana I; Monge A
Bioorg Med Chem; 2003 May; 11(10):2149-56. PubMed ID: 12713824
[TBL] [Abstract][Full Text] [Related]
45. Cathepsin L Inhibitors with Activity against the Liver Fluke Identified From a Focus Library of Quinoxaline 1,4-di-
Ferraro F; Merlino A; Gil J; Cerecetto H; Corvo I; Cabrera M
Molecules; 2019 Jun; 24(13):. PubMed ID: 31247891
[TBL] [Abstract][Full Text] [Related]
46. New 3-methylquinoxaline-2-carboxamide 1,4-di-N-oxide derivatives as anti-Mycobacterium tuberculosis agents.
Ancizu S; Moreno E; Solano B; Villar R; Burguete A; Torres E; Pérez-Silanes S; Aldana I; Monge A
Bioorg Med Chem; 2010 Apr; 18(7):2713-9. PubMed ID: 20233660
[TBL] [Abstract][Full Text] [Related]
47. Synthesis and biological evaluation of novel 2,3-disubstituted quinoxaline derivatives as antileishmanial and antitrypanosomal agents.
Cogo J; Kaplum V; Sangi DP; Ueda-Nakamura T; Corrêa AG; Nakamura CV
Eur J Med Chem; 2015 Jan; 90():107-23. PubMed ID: 25461316
[TBL] [Abstract][Full Text] [Related]
48. Beta-lactam antibiotics with N-oxide side chains. 1. Quinoxaline N-oxides.
Edwards ML; Bambury RE; Ritter HW
J Med Chem; 1976 Feb; 19(2):330-3. PubMed ID: 814237
[TBL] [Abstract][Full Text] [Related]
49. Synthesis and biological evaluation of 3-aryl-quinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives as hypoxic selective anti-tumor agents.
Hu Y; Xia Q; Shangguan S; Liu X; Hu Y; Sheng R
Molecules; 2012 Aug; 17(8):9683-96. PubMed ID: 22890172
[TBL] [Abstract][Full Text] [Related]
50. Novel antimalarial chloroquine- and primaquine-quinoxaline 1,4-di-N-oxide hybrids: Design, synthesis, Plasmodium life cycle stage profile, and preliminary toxicity studies.
Bonilla-Ramirez L; Rios A; Quiliano M; Ramirez-Calderon G; Beltrán-Hortelano I; Franetich JF; Corcuera L; Bordessoulles M; Vettorazzi A; López de Cerain A; Aldana I; Mazier D; Pabón A; Galiano S
Eur J Med Chem; 2018 Oct; 158():68-81. PubMed ID: 30199706
[TBL] [Abstract][Full Text] [Related]
51. Design and synthesis of novel quinoxaline derivatives as potential candidates for treatment of multidrug-resistant and latent tuberculosis.
Santivañez-Veliz M; Pérez-Silanes S; Torres E; Moreno-Viguri E
Bioorg Med Chem Lett; 2016 May; 26(9):2188-93. PubMed ID: 27025343
[TBL] [Abstract][Full Text] [Related]
52. Design, synthesis, antimicrobial activity and molecular docking studies of some novel di-substituted sulfonylquinoxaline derivatives.
Ammar YA; Farag AA; Ali AM; Ragab A; Askar AA; Elsisi DM; Belal A
Bioorg Chem; 2020 Nov; 104():104164. PubMed ID: 32896807
[TBL] [Abstract][Full Text] [Related]
53. New amide derivatives of quinoxaline 1,4-di-N-oxide with leishmanicidal and antiplasmodial activities.
Barea C; Pabón A; Pérez-Silanes S; Galiano S; Gonzalez G; Monge A; Deharo E; Aldana I
Molecules; 2013 Apr; 18(4):4718-27. PubMed ID: 23609622
[TBL] [Abstract][Full Text] [Related]
54. Quinoxaline 1,4-di-N-Oxides: Biological Activities and Mechanisms of Actions.
Cheng G; Sa W; Cao C; Guo L; Hao H; Liu Z; Wang X; Yuan Z
Front Pharmacol; 2016; 7():64. PubMed ID: 27047380
[TBL] [Abstract][Full Text] [Related]
55. Primaquine-quinoxaline 1,4-di-N-oxide hybrids with action on the exo-erythrocytic forms of Plasmodium induce their effect by the production of reactive oxygen species.
Bonilla-Ramírez L; Galiano S; Quiliano M; Aldana I; Pabón A
Malar J; 2019 Jun; 18(1):201. PubMed ID: 31217011
[TBL] [Abstract][Full Text] [Related]
56. New quinoxaline 1, 4-di-N-oxides: anticancer and hypoxia-selective therapeutic agents.
Ismail MM; Amin KM; Noaman E; Soliman DH; Ammar YA
Eur J Med Chem; 2010 Jul; 45(7):2733-8. PubMed ID: 20236735
[TBL] [Abstract][Full Text] [Related]
57. Synthesis of novel quinoxaline-alkynyl derivatives and their anti-Mycobacterium tuberculosis activity.
Raphoko LA; Lekgau K; Lebepe CM; Leboho TC; Matsebatlela TM; Nxumalo W
Bioorg Med Chem Lett; 2021 Mar; 35():127784. PubMed ID: 33422606
[TBL] [Abstract][Full Text] [Related]
58. Quinoxaline derivatives as potential antitrypanosomal and antileishmanial agents.
Cogo J; Cantizani J; Cotillo I; Sangi DP; Corrêa AG; Ueda-Nakamura T; Filho BPD; Martín JJ; Nakamura CV
Bioorg Med Chem; 2018 Aug; 26(14):4065-4072. PubMed ID: 30100019
[TBL] [Abstract][Full Text] [Related]
59. In silico studies of quinoxaline-2-carboxamide 1,4-di-n-oxide derivatives as antimycobacterial agents.
Radwan AA; Abdel-Mageed WM
Molecules; 2014 Feb; 19(2):2247-60. PubMed ID: 24566302
[TBL] [Abstract][Full Text] [Related]
60. Trypanocidal properties, structure-activity relationship and computational studies of quinoxaline 1,4-di-N-oxide derivatives.
Estevez Y; Quiliano M; Burguete A; Cabanillas B; Zimic M; Málaga E; Verástegui M; Pérez-Silanes S; Aldana I; Monge A; Castillo D; Deharo E
Exp Parasitol; 2011 Apr; 127(4):745-51. PubMed ID: 21272583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
